drugset / Trial / NCT03546868

Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease

NCT03546868

Phase 2 Completed 20 enrolled Asan Foundation
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Diagnostic validity of \[18F\]FSPG for assessing disease activity will be assessed in subjects with inflammatory bowel disease.

Timeline

Start
2018-08-14
Primary completion
2019-01-11
Completion
2019-01-11

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FSPG Diagnostic / imaging agent 200 mbq